fashion -WSS

fashion

author：knowledge 2025-09-27 22:48:26 - browse：51

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： WATCH: Why do fingernails fall off when they're damaged?

WSS

Donald Trump's relentless attacks on special counsel Jack Smith

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Diabetes management: Digital health tools fall short, study says

Asbestos ban is immediate, but health effects will linger for decades

Gene therapy has helped boys walk. Can scientists keep it that way?

New guidelines on severe brain injury complicate already difficult decisions

focus

fashion

Wikipedia

New air purifier tech could be key to improving indoor air quality

This gene therapy has record $4.25 million price. It's saved children.

Bright Health sells Medicare Advantage business to Molina

WATCH: Why do fingernails fall off when they're damaged?

Sports medicine is finally prioritizing gender equality

Why are elite athletes different? Take a look at their microbes

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Paxlovid study fails to answer questions over benefit for broader groups

Supreme Court strikes down use of affirmative action

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

focus

With FDA staff opposed to Sarepta therapy, top official intervened

Biotech investment managers search for lucrative opportunities

Gene therapy has helped boys walk. Can scientists keep it that way?

This gene therapy has record $4.25 million price. It's saved children.

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Weight bias in eating disorder treatment complicated by new weight loss drugs

focus

focus

hotspot

hotspot